Gateway 2011: WellSpring Pharmaceutical Canada Corp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: WellSpring Pharmaceutical Canada Corp



Your online Gateway to WellSpring Pharmaceutical Canada Corp in 2011

400 Iroquois Shore Road,
Oakville Ontario L6H 1M5 Canada
1-866-337-4500
Fax: 905-337-7239
http://www.wellspringcmo.com

About WellSpring Pharmaceutical Canada Corp

With WellSpring Pharmaceutical Contract Services our ability is your solution for manufacturing and packaging of virtually all finished non-sterile, solid and semi-solid dose products. We also provide clinical manufacturing, over-encapsulation, labeling, packaging, storage, distribution and returned goods management to support our clients’ most complex clinical trial requirements.


 


Our capabilities include blending, granulation, tablet compression, encapsulation, film coating, and topicals and liquids processing. Extensive packaging capabilities enable tablets or capsules to be bottled or blister-sealed and topical products can be supplied in jars and tubes. Our facility and quality systems have been successfully inspected by FDA and Health Canada.

Please visit WellSpring Pharmaceutical for manufacturing, packaging, analytical and distribution services for clinical and commercial supplies.  Contact us to arrange a convenient time to discuss how we can provide contract services supply chain solutions for virtually all finished non-sterile, liquids, semi-solids  and solid dosage form products.  WellSpring’s outstanding customer service and flexibility will ensure your supply chain needs are met.

 

New Products
and Releases

Brochure

 

For more information:

info@wellspringcmo.com

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here